The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit research and development organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected patients since 2003.
The India office ensures South Asia partnerships and collaboration with Bangladesh, Nepal, and Sri Lanka. Nearly two decades later, DNDi has grown into a network of more than 200 partner institutions that spans the globe. Looking ahead, DNDi launched its new Strategic Plan 2021-2028. The strategic plan charts an eight-year journey to 2028 where DNDi aims to deliver 25 new treatments in its first 25 years. We are eager to reflect on the challenges and drivers of change looming ahead in South Asia.
We were joined by a panel of passionate and committed experts to reflect on the challenges and opportunities pertaining to drug discovery, development, and access for neglected tropical diseases in South Asia.
- Professor Balram Bhargava, Secretary, Department of Health Research MoHFW, GoI and Director General, ICMR
- Dr Renu Swarup, Secretary, DBT and DST, Ministry of Science & Technology, GoI and Chairperson, BIRAC
- Dr VG Somani, Drug Controller General of India, GoI, MoHFW
- Mr K Satish Reddy, Chairman, Dr Reddy’s Laboratories
- Dr Tahmeed Ahmed, Executive Director, International Centre for Diarrhoeal Disease Research, Bangladesh
- Dr Farhat Mantoo, Director General, Médecins Sans Frontières India
- Dr Harish Iyer, Deputy Director, Digital Health and Innovations, Bill & Melinda Gates Foundation